These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29227213)

  • 21. Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.
    Sharkey B; Pudi S; Wallace Moyer I; Zhong L; Prinz B; Baruah H; Lynaugh H; Kumar S; Wittrup KD; Nett JH
    MAbs; 2017; 9(2):257-268. PubMed ID: 27937066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An efficient route to human bispecific IgG.
    Merchant AM; Zhu Z; Yuan JQ; Goddard A; Adams CW; Presta LG; Carter P
    Nat Biotechnol; 1998 Jul; 16(7):677-81. PubMed ID: 9661204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries.
    Fellouse FA; Esaki K; Birtalan S; Raptis D; Cancasci VJ; Koide A; Jhurani P; Vasser M; Wiesmann C; Kossiakoff AA; Koide S; Sidhu SS
    J Mol Biol; 2007 Nov; 373(4):924-40. PubMed ID: 17825836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
    Igawa T
    Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving target cell specificity using a novel monovalent bispecific IgG design.
    Mazor Y; Oganesyan V; Yang C; Hansen A; Wang J; Liu H; Sachsenmeier K; Carlson M; Gadre DV; Borrok MJ; Yu XQ; Dall'Acqua W; Wu H; Chowdhury PS
    MAbs; 2015; 7(2):377-89. PubMed ID: 25621507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity Capture.
    Nesspor TC; Kinealy K; Mazzanti N; Diem MD; Boye K; Hoffman H; Springer C; Sprenkle J; Powers G; Jiang H; La Porte SL; Ganesan R; Singh S; Zwolak A
    Sci Rep; 2020 May; 10(1):7557. PubMed ID: 32372058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
    Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific antibody process development: Assembly and purification of knob and hole bispecific antibodies.
    Giese G; Williams A; Rodriguez M; Persson J
    Biotechnol Prog; 2018 Mar; 34(2):397-404. PubMed ID: 29193902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid optimization and prototyping for therapeutic antibody-like molecules.
    Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
    MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry.
    Yin Y; Han G; Zhou J; Dillon M; McCarty L; Gavino L; Ellerman D; Spiess C; Sandoval W; Carter PJ
    MAbs; 2016; 8(8):1467-1476. PubMed ID: 27610742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.
    Lindhofer H; Mocikat R; Steipe B; Thierfelder S
    J Immunol; 1995 Jul; 155(1):219-25. PubMed ID: 7602098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
    Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
    MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Round optimization for improved discovery of native bispecific antibodies.
    Gueneau F; Ravn U; Fischer N
    Methods; 2019 Feb; 154():51-59. PubMed ID: 30448477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.
    DeNardo DG; Xiong CY; Shi XB; DeNardo GL; DeNardo SJ
    Cancer Biother Radiopharm; 2001 Dec; 16(6):525-35. PubMed ID: 11789029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.